These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32318949)

  • 1. CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreatic Cancer.
    Liu H; Zenati MS; Rieser CJ; Al-Abbas A; Lee KK; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
    Ann Surg Oncol; 2020 Oct; 27(10):3950-3960. PubMed ID: 32318949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer.
    Ghabi EM; Shoucair S; Ding D; Javed AA; Thompson ED; Zheng L; Cameron JL; Wolfgang CL; Shubert CR; Lafaro KJ; Burkhart RA; Burns WR; He J
    J Gastrointest Surg; 2023 Apr; 27(4):691-700. PubMed ID: 36280632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis.
    Okada K; Murakami Y; Uemura K; Kondo N; Nakagawa N; Seo S; Otsuka H; Takahashi S
    Langenbecks Arch Surg; 2020 Aug; 405(5):623-633. PubMed ID: 32592044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.
    Mirkin KA; Hollenbeak CS; Wong J
    Int J Surg; 2016 Oct; 34():96-102. PubMed ID: 27573691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
    Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
    JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
    Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
    J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer.
    Tsai S; George B; Wittmann D; Ritch PS; Krepline AN; Aldakkak M; Barnes CA; Christians KK; Dua K; Griffin M; Hagen C; Hall WA; Erickson BA; Evans DB
    Ann Surg; 2020 Apr; 271(4):740-747. PubMed ID: 30312198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study.
    de Geus SWL; Kasumova GG; Eskander MF; Ng SC; Kent TS; James Moser A; Vahrmeijer AL; Callery MP; Tseng JF
    J Gastrointest Surg; 2018 Feb; 22(2):214-225. PubMed ID: 29235000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection?
    Guo Y; Czeyda-Pommersheim F; Miccio JA; Mahalingam S; Cecchini M; Pahade J
    Abdom Radiol (NY); 2021 Dec; 46(12):5609-5617. PubMed ID: 34557934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nationwide trends and outcomes of neoadjuvant chemotherapy in pancreatic cancer - an analysis of the Swedish national pancreatic cancer registry.
    Sternby H; Andersson B
    Scand J Gastroenterol; 2022 Nov; 57(11):1361-1366. PubMed ID: 35635264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis.
    Ye C; Sadula A; Ren S; Guo X; Yuan M; Yuan C; Xiu D
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):731-740. PubMed ID: 33047181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
    Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M;
    Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease.
    Abdel-Misih SR; Hatzaras I; Schmidt C; Saab TB; Klemanski D; Muscarella P; Melvin WS; Ellison EC; Bloomston M
    Ann Surg Oncol; 2011 Apr; 18(4):1116-21. PubMed ID: 21042945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
    Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
    Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer.
    Aldakkak M; Christians KK; Krepline AN; George B; Ritch PS; Erickson BA; Johnston FM; Evans DB; Tsai S
    HPB (Oxford); 2015 Oct; 17(10):942-52. PubMed ID: 26255895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma.
    Al Abbas AI; Zenati M; Reiser CJ; Hamad A; Jung JP; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2020 Jun; 27(6):2007-2014. PubMed ID: 31898105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancreatic Consortium.
    Ogobuiro I; Collier AL; Khan K; de Castro Silva I; Kwon D; Wilson GC; Schwartz PB; Parikh AA; Hammill C; Kim HJ; Kooby DA; Abbott D; Maithel SK; Snyder RA; Ahmad SA; Merchant NB; Datta J
    Ann Surg Oncol; 2023 Mar; 30(3):1485-1494. PubMed ID: 36316508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.
    Hammad AY; Hodges JC; AlMasri S; Paniccia A; Lee KK; Bahary N; Singhi AD; Ellsworth SG; Aldakkak M; Evans DB; Tsai S; Zureikat A
    JAMA Surg; 2023 Jan; 158(1):55-62. PubMed ID: 36416848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer.
    AlMasri S; Zenati M; Hammad A; Nassour I; Liu H; Hogg ME; Zeh HJ; Boone B; Bahary N; Singhi AD; Lee KK; Paniccia A; Zureikat AH
    JAMA Netw Open; 2022 Jun; 5(6):e2218355. PubMed ID: 35737385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
    Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
    Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.